Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
4.430
-0.080 (-1.77%)
At close: Feb 21, 2025, 4:00 PM
4.410
-0.020 (-0.45%)
After-hours: Feb 21, 2025, 4:39 PM EST
Clene Employees
As of December 31, 2023, Clene had 85 total employees, including 82 full-time and 3 part-time employees. The number of employees decreased by 1 or -1.16% compared to the previous year.
Employees
85
Change (1Y)
-1
Growth (1Y)
-1.16%
Revenue / Employee
$4,953
Profits / Employee
-$423,812
Market Cap
35.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85 | -1 | -1.16% |
| Dec 31, 2022 | 86 | -16 | -15.69% |
| Dec 31, 2021 | 102 | 28 | 37.84% |
| Dec 31, 2020 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Walmart | 2,100,000 |
| PepsiCo | 318,000 |
| Costco Wholesale | 316,000 |
| Anheuser-Busch InBev | 154,450 |
| Unilever | 128,000 |
| The Procter & Gamble Company | 107,000 |
| Mondelez International | 90,000 |
| Philip Morris International | 82,700 |
CLNN News
- 2 months ago - FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - GlobeNewsWire
- 5 months ago - Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data - GlobeNewsWire
- 6 months ago - Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 7 months ago - IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - GlobeNewsWire
- 7 months ago - Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 8 months ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 8 months ago - Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS - GlobeNewsWire